Payment overview · 2025
General Payments
$1,041.45
37 reported records · 14 companies
Healthcare provider profile · identity verified
James Arthur Rice, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · MOUNT VERNON, IN · NPI 1760417513
Verified facts
What the public records show
CMS Open Payments records show James Arthur Rice, D.O. received $1,041.45 in general payments during 2025 across 37 reported records.
AstraZeneca Pharmaceuticals LP accounted for 50.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Farxiga, Jardiance, Ozempic, Rexulti, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 204 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $525.90 | 50.5% | 13 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $190.70 | 18.3% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $66.90 | 6.4% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $59.80 | 5.7% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $37.30 | 3.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $29.97 | 2.9% | 2 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $19.48 | 1.9% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $19.17 | 1.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.23 | 1.6% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.76 | 1.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.47 | 1.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.38 | 1.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.27 | 1.4% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.12 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,041.45 | 37 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $356.34 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $150.28 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $143.98 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $94.85 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $66.90 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $59.80 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $39.82 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $20.08 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $19.17 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $17.23 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.22 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.22 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.09 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.77 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.77 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $15.76 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.47 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.47 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.38 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.27 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.20 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.20 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.20 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.12 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $12.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 60 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 204 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 88 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 80 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 91 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
17 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
88 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
60 | 60 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
48 | 41 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
91 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
80 | 16 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
204 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 649 | 163 |
| Levothyroxine Sodium | Levothyroxine Sodium | 579 | 137 |
| Amlodipine Besylate | Amlodipine Besylate | 563 | 140 |
| Omeprazole | Omeprazole | 356 | 91 |
| Metoprolol Succinate | Metoprolol Succinate | 345 | 94 |
| Lisinopril | Lisinopril | 310 | 67 |
| Losartan Potassium | Losartan Potassium | 262 | 66 |
| Metformin Hcl | Metformin Hcl | 250 | 56 |
| Gabapentin | Gabapentin | 237 | 43 |
| Eliquis | Apixaban | 204 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 191 | 54 |
| Tamsulosin Hcl | Tamsulosin Hcl | 188 | 52 |
| Prednisone | Prednisone | 184 | 120 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 164 | 31 |
| Sertraline Hcl | Sertraline Hcl | 160 | 31 |
| Azithromycin | Azithromycin | 155 | 108 |
| Pantoprazole Sodium | Pantoprazole Sodium | 149 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 135 | 34 |
| Meloxicam | Meloxicam | 135 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 132 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 131 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 122 | 29 |
| Allopurinol | Allopurinol | 117 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 117 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 117 | 42 |
| Tramadol Hcl | Tramadol Hcl | 116 | 30 |
| Furosemide | Furosemide | 112 | 37 |
| Montelukast Sodium | Montelukast Sodium | 108 | 26 |
| Donepezil Hcl | Donepezil Hcl | 106 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 106 | 22 |
| Memantine Hcl | Memantine Hcl | 106 | 14 |
| Simvastatin | Simvastatin | 105 | 27 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 103 | 28 |
| Glimepiride | Glimepiride | 102 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 99 | 22 |
| Clonazepam | Clonazepam | 98 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 91 | 17 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 90 | 21 |
| Farxiga | Dapagliflozin Propanediol | 88 | 18 |
| Lorazepam | Lorazepam | 86 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 83 | 21 |
| Ozempic | Semaglutide | 80 | 16 |
| Potassium Chloride | Potassium Chloride | 79 | 26 |
| Atenolol | Atenolol | 76 | 20 |
| Famotidine | Famotidine | 74 | 16 |
| Warfarin Sodium | Warfarin Sodium | 74 | suppressed |
| Januvia | Sitagliptin Phosphate | 73 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 72 | 40 |
| Temazepam | Temazepam | 67 | 11 |
| Xarelto | Rivaroxaban | 63 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 60 | 60 |
| Paroxetine Hcl | Paroxetine Hcl | 59 | 13 |
| Trazodone Hcl | Trazodone Hcl | 59 | 16 |
| Carvedilol | Carvedilol | 58 | 19 |
| Bupropion Hcl Sr | Bupropion Hcl | 56 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 56 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 55 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 54 | 14 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 48 | 41 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 46 | 35 |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | suppressed |
| Olanzapine | Olanzapine | 46 | suppressed |
| Myrbetriq | Mirabegron | 44 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 44 | suppressed |
| Mirtazapine | Mirtazapine | 40 | 15 |
| Colestipol Hcl | Colestipol Hcl | 39 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 39 | suppressed |
| Ezetimibe | Ezetimibe | 39 | suppressed |
| Spironolactone | Spironolactone | 39 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | suppressed |
| Fluconazole | Fluconazole | 37 | 12 |
| Levofloxacin | Levofloxacin | 37 | 30 |
| Amoxicillin | Amoxicillin | 36 | 30 |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 36 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 36 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 35 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | suppressed |
| Synthroid | Levothyroxine Sodium | 35 | suppressed |
| Twinrix | Hepatitis A And B Vaccine/Pf | 35 | 31 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 33 | 12 |
| Estradiol | Estradiol | 33 | suppressed |
| Trulicity | Dulaglutide | 33 | suppressed |
| Jardiance | Empagliflozin | 31 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 31 | suppressed |
| Rexulti | Brexpiprazole | 30 | suppressed |
| Sucralfate | Sucralfate | 30 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 21 |
| Symbicort | Budesonide/Formoterol Fumarate | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 28 | 13 |
| Nitroglycerin | Nitroglycerin | 28 | 17 |
| Vascepa | Icosapent Ethyl | 28 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 27 | suppressed |
| Vraylar | Cariprazine Hcl | 27 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 26 | suppressed |
| Bumetanide | Bumetanide | 26 | suppressed |
| Cephalexin | Cephalexin | 26 | 13 |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | 13 |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 25 | 25 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 21 |
| Celecoxib | Celecoxib | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Repatha Sureclick | Evolocumab | 24 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Ibuprofen | Ibuprofen | 23 | 11 |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Gemtesa | Vibegron | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Telmisartan | Telmisartan | 21 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 19 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 17 | suppressed |
| Prolia | Denosumab | 17 | 12 |
| Acyclovir | Acyclovir | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 12 |
| Dropsafe Pen Needle | Pen Needle, Diabetic, Safety | 16 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 11 |
| Clindamycin Hcl | Clindamycin Hcl | 14 | 14 |
| Glipizide | Glipizide | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Cimetidine | Cimetidine | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Restasis | Cyclosporine | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Roflumilast | Roflumilast | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,041.45 · 37 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, AREXVY, Auvelity, BREZTRI, CAPLYTA, COMIRNATY, ELIQUIS, EVENITY, FARXIGA, JARDIANCE, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, Senza, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, Wegovy, XIFAXAN | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error